ECM
SAGE

Endurant Capital Management’s Sage Therapeutics SAGE Stock Holding History

Endurant Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-23,588
Closed -$1.44M – 70
2020
Q3 		$1.44M Buy
+23,588
New +$1.2M 0.43% 51

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Endurant Capital Management's SAGE Position: Q4 2020 in Review

Endurant Capital Management sold out of Sage Therapeutics (SAGE) in Q4 2020, closing a stake of 23,588 shares — an estimated $1.44M sold.

Endurant Capital Management first reported a position in SAGE in Q3 2020 and held it in 1 quarter. The position peaked at $1.44M in Q3 2020. 248 funds tracked by Wall St. Rank hold SAGE as of Q4 2020.

  • Endurant Capital Management reported no remaining Sage Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Endurant Capital Management sold 23,588 Sage Therapeutics shares in Q4 2020, an estimated $1.44M.
  • Endurant Capital Management first reported a position in Sage Therapeutics in Q3 2020 and held it in 1 quarter.
  • Endurant Capital Management's Sage Therapeutics position peaked at $1.44M in Q3 2020.
  • 248 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2020.

Based on Endurant Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.